 | Vol. 11.12 – 30 March, 2022 |
| |
|
|
| Through comparative chromatin state and gene expression analyses in ovarian CSCs vs. non-CSCs, researchers identified FOXK2 as a highly expressed stemness-specific transcription factor in ovarian cancer. [Journal of Clinical Investigation] |
|
|
|
 | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported that FOSL1, a component of AP-1 transcription factor complexes, was a key player in regulating proneural to mesenchymal transition. FOSL1 was predominantly expressed in the mesenchymal subtype, but not the proneural subtype of glioblastoma stem cells. [Molecular Therapy] |
|
|
|
| Scientists explored the effect of the plasma-activated medium on lung cancer cells in vitro and in vivo by using a 3D cell culture model. [Oxidative Medicine and Cellular Longevity] |
|
|
|
| Scientists identified and isolated chemoradiotherapy-resistant CSCs in quiescent state with high capacity of tumor-initiation and tumorsphere formation from three types of breast tumors in mice. [Oncogene] |
|
|
|
| Whether TGFβ promoted stemness and invasiveness simultaneously via epithelial-mesenchymal transition remains unclear. The authors established a breast cancer cell model expressing red fluorescent protein under the E-cadherin promoter. [Molecular Oncology] |
|
|
|
| Scientists identified that the treatment of levobupivacaine suppressed the proliferation of osteosarcoma cells in vitro, and suggested that it might act as a potential therapeutic candidate for osteosarcoma by targeting CSCs. [Aging] |
|
|
|
| Investigators reported a biologically stable copper(II) complex based on the active site of type I copper electron transport proteins. [Dalton Transactions] |
|
|
|
| Scientists evaluated the selective inhibition of α-mangostin on CSCs in colorectal cancer and the suppressive effect on 5-fluorouracil-induced CSCs. [BMC Cancer] |
|
|
|
| Researchers investigated the effect of ubiquitin-specific protease 1 depletion with chemotherapeutant doxorubicin on hepatocellular carcinoma cells. [Anti-Cancer Drugs] |
|
|
|
|
| At present, the isolation and identification of CSCs from many solid tumors are still quite difficult, mainly due to the lack of specific molecular markers of CSCs. The authors summarize CSC surface markers and functional markers in the urinary system. [Stem Cells International] |
|
|
|
|
| OncoTEX, Inc. announced its novel cancer-fighting drug candidate, OxaliTEX, has received a notice of allowance for patent in Korea. [OncoTEX, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
|
|
|
| Luxembourg Institute of Health – Strassen, Luxembourg |
|
|
|
| CRUK Manchester Institute – Manchester, England, United Kingdom |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| Oregon Health and Science University – Portland, Oregon, United States |
|
|
|
|